Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: PARP inhibitors for advanced prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.19
Views: 497

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Dr Ignacio Duran comments on data from the PROfound trial during a press conference at the 2019 ESMO congress.

This was a trial evaluating the PARP inhibitor olaparib vs new hormonal agents in patients with metastatic, pre-treated prostate cancer whose cancer cells had faulty DNA repair genes.

Watch the press conference here.

Watch Prof Maha Hussain's interview with ecancer here.

Read more about the study here

Related videos

follow us

CLL Janssen

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation